Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Os Therapies Incorporated (OSTX)

Os Therapies Incorporated (OSTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 52,117
  • Shares Outstanding, K 35,214
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,880 K
  • EBIT $ -20 M
  • EBITDA $ -18 M
  • 60-Month Beta -4.02
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 12.88

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.20
  • Number of Estimates 2
  • High Estimate -0.18
  • Low Estimate -0.22
  • Prior Year -0.24
  • Growth Rate Est. (year over year) +16.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4200 +0.35%
on 12/31/25
2.0850 -31.65%
on 12/10/25
-0.3650 (-20.39%)
since 11/28/25
3-Month
1.4200 +0.35%
on 12/31/25
2.1300 -33.10%
on 10/09/25
-0.5350 (-27.30%)
since 09/30/25
52-Week
1.1200 +27.23%
on 04/10/25
7.0000 -79.64%
on 01/15/25
-3.2750 (-69.68%)
since 12/30/24

Most Recent Stories

More News
Pivotal Cancer Trials Gain Momentum as Regulatory Clarity Emerges

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The FDA issued multiple breakthrough approvals for oncology drugs in November 2025, marking a transformative...

ONCY : 0.8812 (-0.67%)
ZNTL : 1.3350 (+0.38%)
NUVB : 9.03 (+1.01%)
OSTX : 1.4000 (-5.41%)
MAIA : 1.5201 (+14.29%)
OS Therapies Announces Successful Type C Meeting with US FDA Regarding Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

FDA confirmed that data from single-arm studies in rare diseases, such as in ultra-rare deadly pediatric cancer osteosarcoma, could support a Biologics Licensing Application (BLA) under Accelerated Approval...

OSTX : 1.4000 (-5.41%)
OS Therapies Announces Successful pre-Marketing Authorisation Application Meeting with UK MHRA Regarding the Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

Alignment achieved on all key points surrounding non-clinical, CMC and post-market authorization confirmatory study designBiomarker data advanced as key pre-specified surrogate clinical efficacy endpoint,...

OSTX : 1.4000 (-5.41%)
OS Therapies Announces FDA PDUFA Waiver & EMA Grants Union Marketing Authorisation Eligibility

U.S. FDA grants waiver of application fee for BLA Filing of OST-HER2Scheduled pre-Marketing Authorisation Application meeting with United Kingdom's Medicines and Healthcare products Regulatory Agency on...

OSTX : 1.4000 (-5.41%)
OS Therapies Receives Non-Proprietary Name 'daznelimgene lisbac' for OST-HER2 from World Health Organization

New York, New York--(Newsfile Corp. - November 25, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer immunotherapies, today announced...

OSTX : 1.4000 (-5.41%)
OS Therapies to Spinoff OS Animal Health into Standalone Public Company

Successful preliminary discussion with NYSE representatives and potential investorsOS Therapies shareholders to receive direct equity participation in new listing'Shelter Me: Cancer Pioneers' film featuring...

OSTX : 1.4000 (-5.41%)
OS Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update

Type C Meeting with US FDA set for December 11, 2025 to address key items following August 27, 2025 End of Phase 2 Meeting regarding Phase 2b clinical trial of OST-HER2: prevention or delay of recurrent,...

OSTX : 1.4000 (-5.41%)
OS Therapies Announces Overall and Event Free Survival Key Subgroup Data for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

New York, New York--(Newsfile Corp. - October 22, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology...

OSTX : 1.4000 (-5.41%)
OS Therapies Granted Final Type C Meeting by U.S. FDA and pre-MAA Meeting by U.K. MHRA for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

Final FDA Type C Meeting December 11, 2025 - biomarker data to be availableOctober 10, 2025 FDA/Osteosarcoma Institute Workshop narrows focus for OST-HER2 overall survival, biomarker correlation & canine...

OSTX : 1.4000 (-5.41%)
OS Therapies Announces Statistically Significant Positive Final 2-Year Overall Survival Data from Phase 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully-Resected, Pulmonary Metastatic Osteosarcoma

75% of OST-HER2 treated patients achieved 2-year overall survival compared with 40% in the historical control group (p < 0.0001)100% of patients who achieved 12 month event free survival achieved 2 year...

OSTX : 1.4000 (-5.41%)

Business Summary

OS Therapies Incorporated is a clinical stage oncology company focused on the identification, development and commercialization of treatments for Osteosarcoma and other solid tumors. The company's lead asset consists OST-HER2. OS Therapies Incorporated is based in NEW YORK.

See More

Key Turning Points

3rd Resistance Point 1.5933
2nd Resistance Point 1.5467
1st Resistance Point 1.5133
Last Price 1.4000
1st Support Level 1.4333
2nd Support Level 1.3867
3rd Support Level 1.3533

See More

52-Week High 7.0000
Fibonacci 61.8% 4.7538
Fibonacci 50% 4.0600
Fibonacci 38.2% 3.3662
Last Price 1.4000
52-Week Low 1.1200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar